↓ Skip to main content

Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature

Overview of attention for article published in Experimental Hematology & Oncology, August 2017
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
31 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature
Published in
Experimental Hematology & Oncology, August 2017
DOI 10.1186/s40164-017-0082-5
Pubmed ID
Authors

Saeed Mohammadi, Amir Hossein Norooznezhad, Ashraf Malek Mohammadi, Hajar Nasiri, Mohsen Nikbakht, Najmaldin Saki, Mohammad Vaezi, Kamran Alimoghaddam, Ardeshir Ghavamzadeh

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been considered as a valuable approach in treatment of numerous malignant and none malignant hematologic disorders. However, relapse and poor graft function (PGF) after allo-SCT remain to be controversial issues which may affect the transplantation outcome. Relevant articles were searched in MEDLINE database (2000-2016) using keywords and phrases: donor lymphocyte infusions, allogeneic stem cells transplantation, relapsed hematologic malignancies, booster schedules, cell dose, laboratory monitoring protocols and technical aspects of apheresis. Relapse of disease and PGF could be reduced via noting some main points such as choosing the suitable time and patient for donor lymphocyte infusion (DLI) and also determination of patients who ought to candidate for second allogeneic HSCT or for the use of stem cell boost. DLI and stem cell booster are promising treatment strategies noted in this review. Finally, this paper discusses indications and technical aspects of DLI and stem cell booster in hematological malignancies and emphasizes their therapeutic or pre-emptive potentials.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 23%
Student > Master 4 13%
Student > Doctoral Student 3 10%
Other 3 10%
Professor 2 6%
Other 6 19%
Unknown 6 19%
Readers by discipline Count As %
Medicine and Dentistry 14 45%
Biochemistry, Genetics and Molecular Biology 2 6%
Nursing and Health Professions 2 6%
Engineering 2 6%
Agricultural and Biological Sciences 2 6%
Other 3 10%
Unknown 6 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 August 2017.
All research outputs
#20,444,703
of 22,999,744 outputs
Outputs from Experimental Hematology & Oncology
#241
of 298 outputs
Outputs of similar age
#277,432
of 318,005 outputs
Outputs of similar age from Experimental Hematology & Oncology
#5
of 5 outputs
Altmetric has tracked 22,999,744 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 298 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 318,005 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.